SCHEMBL5715255

SCHEMBL5715255

O=C(O)c1ccc(CN2CCN(C(=O)Oc3ccc(N4C(=O)C5CCCCC5C4=O)cn3)CC2)nc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
HRH3 Q9Y5N1 4/20 0.38
KMT2A Q03164 3/20 0.37
POLB P06746 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MEN1 O00255 2/20 0.35
MAPT P10636 3/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
ACHE P22303 2/20 0.34
HCAR3 P49019 1/20 0.34
CNR1 P21554 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6101871 0.90 ALDH1A1 (0.38) ALDH1A1GAAHPGDHRH3KMT2A
SCHEMBL5714711 0.86 KDM4E (0.48) ALDH1A1KMT2APOLBL3MBTL1MEN1
SCHEMBL5715161 0.85 ALDH1A1 (0.37) ALDH1A1GAAHPGDHRH3KMT2A
SCHEMBL5715200 0.85 HRH3 (0.46) ALDH1A1GAAHPGDHRH3KMT2A
SCHEMBL5714590 0.84 MGLL (0.37) ALDH1A1GAAHPGDHRH3KMT2A
SCHEMBL5713912 0.82 HRH3 (0.38) ALDH1A1HRH3KMT2AL3MBTL1MEN1
SCHEMBL5714225 0.82 KMT2A (0.43) ALDH1A1KMT2APOLBL3MBTL1MEN1
SCHEMBL5687328 0.80 KMT2A (0.42) ALDH1A1GAAHPGDKMT2APOLB
SCHEMBL5715004 0.80 ALDH1A1 (0.38) ALDH1A1GAAHPGDHRH3KMT2A
SCHEMBL5714634 0.80 KDM4E (0.47) ALDH1A1KMT2APOLBL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL ALDH1A1 1504/4885GAA 84/4885HPGD 1255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.